← Back to Search
Alkylating agents
Multi-agent Chemotherapy + Olaparib and Pembrolizumab for Pancreatic Cancer
Baltimore, MD
Phase 2
Recruiting
Led By Dung Le, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥18 years.
Patients must not have received prior treatment for pancreatic cancer.
Must not have
Is taking a moderate or strong CYP3A inhibitor.
Has received prior therapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan, or PARP inhibitor.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new combination of drugs to treat pancreatic cancer.
See full description
Who is the study for?
This trial is for adults with untreated metastatic pancreatic ductal cancer who have stable or progressive disease after chemotherapy. They must be in good physical condition, understand the study, and agree to use birth control. Excluded are those planning surgery, recent chemo or investigational drug users, with autoimmune diseases, uncontrolled illnesses, certain prior treatments or allergies to monoclonal antibodies.Check my eligibility
What is being tested?
The trial tests maintenance therapy with Olaparib and Pembrolizumab following a multi-agent low dose chemotherapy regimen (GAX-CI) consisting of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin and Irinotecan in patients who haven't been treated before for their pancreatic cancer.See study design
What are the potential side effects?
Possible side effects include nausea from chemotherapy drugs; fatigue; blood cell count changes leading to infection risk; allergic reactions; organ inflammation due to immunotherapy agents like Pembrolizumab; and potential complications from Olaparib affecting blood cells and kidneys.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
show original
Select...
I have not had any treatment for pancreatic cancer.
show original
Select...
I am willing to undergo a tumor biopsy.
show original
Select...
My organ and bone marrow functions meet the required levels.
show original
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
show original
Select...
I will use an approved method of birth control during the study.
show original
Select...
My pancreatic cancer has spread and is confirmed by tests.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently taking medication that strongly affects liver enzymes.
show original
Select...
I have been treated with specific cancer drugs like gemcitabine or cisplatin.
show original
Select...
I have another cancer that is getting worse and needs treatment.
show original
Select...
I have had radiation therapy for pancreatic cancer.
show original
Select...
I have had a transplant of tissue, organ, or bone marrow from another person.
show original
Select...
I need daily oxygen support.
show original
Select...
I need treatment to stop my cancer from growing.
show original
Select...
I am HIV positive.
show original
Select...
I have an infection that is not responding to treatment.
show original
Select...
I have a serious wound.
show original
Select...
I have not had encephalitis, meningitis, or uncontrolled seizures in the last year.
show original
Select...
I am not being considered for surgery.
show original
Select...
I have a serious illness that is not under control.
show original
Select...
I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.
show original
Select...
I have had lung inflammation that needed steroids.
show original
Select...
I am not pregnant or breastfeeding.
show original
Select...
I had surgery less than 28 days before starting the trial medication.
show original
Select...
I have had cancer spread to my brain or spinal cord.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Progression-free Survival (PFS) after 6 months according to IRECIST criteria.
Progression-free Survival (PFS) after 6 months according to RECIST 1.1 criteria.
Secondary study objectives
Number of participants experiencing grade 3 or above drug-related toxicities
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, CapecitabineExperimental Treatment7 Interventions
Maintenance of Pembrolizumab and Olaparib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
2013
Completed Phase 3
~4280
Pembrolizumab
2017
Completed Phase 3
~2630
Olaparib
2017
Completed Phase 4
~2310
Nab-paclitaxel
2014
Completed Phase 3
~2490
Gemcitabine
2017
Completed Phase 3
~1320
Cisplatin
2013
Completed Phase 3
~3040
Irinotecan
2017
Completed Phase 3
~2520
Find a Location
Closest Location:Johns Hopkins· Baltimore, MD
Who is running the clinical trial?
Merck Sharp & Dohme LLCIndustry Sponsor
4,088 Previous Clinical Trials
5,224,237 Total Patients Enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
576 Previous Clinical Trials
33,569 Total Patients Enrolled
Dung Le, MDPrincipal InvestigatorSKCCC Johns Hopkins Medical Institution
12 Previous Clinical Trials
596 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I am willing to undergo a tumor biopsy.My cancer has worsened despite treatment before completing 6 cycles of GAX-CI.I have not had any treatment for pancreatic cancer.My disease has not worsened after 6 treatments with GAX-CI.I am not pregnant and will follow the study's birth control requirements.I am currently taking medication that strongly affects liver enzymes.My organ and bone marrow functions meet the required levels.I haven't had any live vaccines, allergy treatments, growth factors, or major surgery in the last 30 days.You have a disease that can be measured using specific medical guidelines.You have had a bad reaction to any kind of monoclonal antibody.I am fully active or restricted in physically strenuous activity but can do light work.I will use an approved method of birth control during the study.I have been treated with specific cancer drugs like gemcitabine or cisplatin.I have another cancer that is getting worse and needs treatment.My pancreatic cancer has spread and is confirmed by tests.I have had radiation therapy for pancreatic cancer.I have had a transplant of tissue, organ, or bone marrow from another person.I need daily oxygen support.I understand the study, its risks, and how to manage side effects.I need treatment to stop my cancer from growing.I am HIV positive.I have an infection that is not responding to treatment.I have a serious wound.I have not had encephalitis, meningitis, or uncontrolled seizures in the last year.I am not being considered for surgery.I have had chemotherapy in the last 5 years.I have a serious illness that is not under control.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.You have a current autoimmune disease that is not under control.I have had lung inflammation that needed steroids.I have an autoimmune disease or have been on steroids recently.I am not pregnant or breastfeeding.I had surgery less than 28 days before starting the trial medication.I have had cancer spread to my brain or spinal cord.I have active Hepatitis B or C, or I am Hepatitis C antibody positive but viral load negative.
Research Study Groups:
This trial has the following groups:- Group 1: Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.